[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614378":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":11,"centralContacts":15,"locations":10,"responsibleParty":21,"collaborators":24,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":10,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":10,"studyType":44,"phases":10,"briefSummary":45,"conditions":46,"keywords":10,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"China-Japan Friendship Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"ICIACI-Rehab Cohort",null,[12],{"name":13,"affiliation":5,"role":14},"Jingyi Ren, Professor","PRINCIPAL_INVESTIGATOR",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Chengcheng Li, Dr","CONTACT","010-84206809","lcc77983@126.com",{"type":14,"investigatorFullName":22,"investigatorTitle":23,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jingyi Ren","Professor of medicine(Cardiology), Deputy Director of the Cardiology Department and Director of the Heart Failure Center",[25,27,29],{"name":26,"class":6},"Weifang Hospital of Traditional Chinese Medicine",{"name":28,"class":6},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"name":30,"class":6},"Second Affiliated Hospital of Nanchang University","100614378","monitoring-and-rehabilitation-for-iciaci-rehabilitationa-cohort-study-100614378",false,"NCT07278817","Monitoring and Rehabilitation for ICIACI Rehabilitation：A Cohort Study","Study on the Monitoring of Traditional Chinese and Western Medicine Characteristics and Rehabilitation Program for ICIAM：A Cohort Study","Inclusion Criteria:\n\n* Aged 18 to 80 years, inclusive\n* Malignancy confirmed by cytology or histopathology\n* Diagnosis of ICIACI following ICI therapy\n* Assessed by the Multidisciplinary Team for Immune-Related Adverse Events as clinically recovered and entering the rehabilitation.\n\nExclusion Criteria:\n\n* Diagnosis of fulminant myocarditis or cardiac function of NYHA IV\n* Clear evidence suggesting cardiac injury not attributable to ICIs\n* Concurrent acute cardiovascular events or malignant arrhythmias\n* Coexisting severe immune-related adverse events affecting other organ systems\n* Associated severe systemic diseases, such as severe hepatic or renal insufficiency, or severe infection.","ALL","18 Years","80 Years",{"count":42,"type":43},340,"ESTIMATED","OBSERVATIONAL","Immune checkpoint inhibitor-associated cardiac injury (ICIACI) is a low-incidence but highly fatal adverse event. A significant knowledge gap exists regarding the disease characteristics and recovery status of patients during the ICIACI convalescent phase. The objectives of this study are to establish a national, multicenter cohort for this patient population and to comprehensively describe their clinical profiles from an integrated Traditional Chinese and Western medicine standpoint, as well as their current rehabilitation status.",[47],"Immune Checkpoint Inhibitor-Related Myocarditis","NOT_YET_RECRUITING","2025-12-11",{"date":51,"type":52},"2025-12-12","ACTUAL",{"date":54,"type":43},"2025-12-30",{"date":56,"type":43},"2028-07-31",{"name":5,"class":6}]